DK3986897T3 - EGFR-hæmmer til cancerbehandling - Google Patents

EGFR-hæmmer til cancerbehandling Download PDF

Info

Publication number
DK3986897T3
DK3986897T3 DK20734871.5T DK20734871T DK3986897T3 DK 3986897 T3 DK3986897 T3 DK 3986897T3 DK 20734871 T DK20734871 T DK 20734871T DK 3986897 T3 DK3986897 T3 DK 3986897T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
egfr inhibitor
egfr
inhibitor
cancer
Prior art date
Application number
DK20734871.5T
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Sander Ulrike Obst
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3986897T3 publication Critical patent/DK3986897T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK20734871.5T 2019-06-21 2020-06-19 EGFR-hæmmer til cancerbehandling DK3986897T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (en) 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3986897T3 true DK3986897T3 (da) 2023-10-30

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20734871.5T DK3986897T3 (da) 2019-06-21 2020-06-19 EGFR-hæmmer til cancerbehandling

Country Status (28)

Country Link
US (4) US20220315593A1 (da)
EP (4) EP3986898B1 (da)
JP (4) JP2022537769A (da)
KR (1) KR20220024105A (da)
CN (3) CN113993873A (da)
AR (4) AR119206A1 (da)
AU (1) AU2020295703A1 (da)
BR (1) BR112021025445B1 (da)
CA (1) CA3140485A1 (da)
CL (1) CL2021003408A1 (da)
CO (1) CO2021017173A2 (da)
CR (1) CR20210624A (da)
DK (1) DK3986897T3 (da)
ES (1) ES2961187T3 (da)
FI (1) FI3986897T3 (da)
HR (1) HRP20231276T1 (da)
HU (1) HUE063676T2 (da)
IL (1) IL288522A (da)
LT (1) LT3986897T (da)
MA (1) MA56508B1 (da)
MX (1) MX2021015464A (da)
PE (1) PE20220576A1 (da)
PL (1) PL3986897T3 (da)
PT (1) PT3986897T (da)
RS (1) RS64720B1 (da)
SI (1) SI3986897T1 (da)
TW (4) TW202115071A (da)
WO (4) WO2020254568A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217923A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag New indazole derivatives
WO2023217924A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525927A (ja) 2008-06-25 2011-09-29 シェーリング コーポレイション 複素環式抗菌剤の合成および使用
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP6771491B2 (ja) 2015-05-14 2020-10-21 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ｅｂｎａ１阻害剤およびその使用方法
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
MX2020014085A (es) * 2018-06-29 2021-03-09 Hoffmann La Roche Compuestos.

Also Published As

Publication number Publication date
AR119206A1 (es) 2021-12-01
TW202115074A (zh) 2021-04-16
LT3986897T (lt) 2023-11-10
ES2961187T3 (es) 2024-03-08
SI3986897T1 (sl) 2023-12-29
US20220315592A1 (en) 2022-10-06
CN113966335A (zh) 2022-01-21
IL288522A (en) 2022-01-01
EP3986898B1 (en) 2023-03-15
HRP20231276T1 (hr) 2024-02-02
TW202115071A (zh) 2021-04-16
CN113993872A (zh) 2022-01-28
MA56508A (fr) 2022-04-27
EP3986895B1 (en) 2023-03-15
EP3986897A1 (en) 2022-04-27
CR20210624A (es) 2022-02-14
MA56508B1 (fr) 2023-11-30
EP3986895A1 (en) 2022-04-27
AU2020295703A1 (en) 2022-01-06
PE20220576A1 (es) 2022-04-20
CN114008049A (zh) 2022-02-01
CL2021003408A1 (es) 2022-10-14
CN113993873A (zh) 2022-01-28
TW202115053A (zh) 2021-04-16
JP2022537191A (ja) 2022-08-24
EP3986897B1 (en) 2023-08-30
WO2020254565A1 (en) 2020-12-24
JP2022537769A (ja) 2022-08-29
WO2020254572A1 (en) 2020-12-24
CO2021017173A2 (es) 2022-01-17
RS64720B1 (sr) 2023-11-30
EP3986896B1 (en) 2023-03-15
AR119209A1 (es) 2021-12-01
EP3986896A1 (en) 2022-04-27
CA3140485A1 (en) 2020-12-24
WO2020254562A1 (en) 2020-12-24
US20220135571A1 (en) 2022-05-05
BR112021025445B1 (pt) 2024-02-27
KR20220024105A (ko) 2022-03-03
PT3986897T (pt) 2023-10-23
FI3986897T3 (fi) 2023-10-20
JP2022538403A (ja) 2022-09-02
BR112021025445A2 (pt) 2022-02-01
US20230054473A1 (en) 2023-02-23
MX2021015464A (es) 2022-01-24
PL3986897T3 (pl) 2024-01-22
EP3986898A1 (en) 2022-04-27
HUE063676T2 (hu) 2024-01-28
AR119210A1 (es) 2021-12-01
AR119208A1 (es) 2021-12-01
JP2022538055A (ja) 2022-08-31
TW202115072A (zh) 2021-04-16
US20220315593A1 (en) 2022-10-06
WO2020254568A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
MA52812A (fr) Inhibiteurs de sarm1
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
KR20180084772A (ko) 암 치료를 위한 조합 치료법
MA55909A (fr) Inhibiteurs de cdk
EA201991818A1 (ru) Лечение рака
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
IL287907A (en) Cancer treatment methods
MA52809A (fr) Inhibiteurs de sarm1
IL282041A (en) Egfr inhibitors for treating keratodermas
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
EP3852762A4 (en) NEW EGFR QUINAZOLINE INHIBITORS
IL274198A (en) Use of Nox inhibitors to treat cancer
MA51611A (fr) Inhibiteurs de pi4kiiibêta
IL288522A (en) Inhibitor of egfr for cancer treatment
DK3576740T3 (da) Cancerbehandling
DK3638293T3 (da) Sammensætninger til behandling af cancer
MA54932A (fr) Traitement contre le cancer
GB201909468D0 (en) Compounds for treating cancer
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi